Tesetaxel: Phase IIa data

In an open-label Phase IIa trial in 32 evaluable patients who had progressed on chemotherapy regimens that had included an anthracycline as standard therapy, 27 or 35 mg/m 2 tesetaxel once every 3 weeks produced 13 partial responses, plus 11 cases of stable disease. Neutropenia was the dose-limiting adverse event. ...